Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 441Magnetic Resonance Spectroscopy 340pembrolizumab 286Biopsy 242Carboplatin 228Cisplatin 193Cyclophosphamide 177Paclitaxel 160Nivolumab 152Gemcitabine 147Bevacizumab 123Radiotherapy 120Dexamethasone 110Pemetrexed 101fludarabine 95Fluorouracil 95atezolizumab 90Radiation 90venetoclax 89Docetaxel 88Doxorubicin 86Oxaliplatin 85durvalumab 84Rituximab 83Leucovorin 81Capecitabine 75Prednisone 72Lenalidomide 69X-Rays 67Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡